Wednesday, September 30 closes out the quarter with one of the most consequential earnings reports of the year and a small biotech still riding the wave of a headline-grabbing pharma deal. Micron Technology reports fiscal fourth-quarter results after the close, carrying a stock up more than 270% year to date into a print Wall Street expects to be a beat, while Summit Therapeutics is trending up more than 20% for a second straight session after AstraZeneca committed $2 billion to its lead cancer drug. Layer in five overlooked mid-cap earnings reports spanning food, furniture, software and uranium, and Wednesday has more genuine catalysts packed into one session than most weeks combined.

What’s Setting Up Wednesday’s Session:

Here’s what to watch when trading resumes Wednesday.

1. Micron Technology (MU) | Last Close $1,065.08 | Reports After Wednesday’s Close

The Year’s Biggest Semiconductor Earnings Test Arrives

Micron reports fiscal fourth-quarter results after Wednesday’s close, and the stakes could hardly be higher for a stock up 273% year to date and 570% over the past year on the strength of the AI-driven memory chip supercycle.

Full Data & Technical Snapshot:

Catalysts & News: JPMorgan’s Harlan Sur reiterated an Overweight rating and a $1,540 target, calling for Micron to beat Street estimates on tight memory supply, while Bank of America’s Vivek Arya framed the key question as whether gross margins can hold in the mid-80% range through fiscal 2027 rather than near-term pricing. One trader on Polymarket put the odds of an EPS beat at 96%.

Bull Case: Micron trades at just 7x forward earnings despite a business riding the strongest memory cycle in the company’s history, and eight straight quarters of EPS beats support the case that Wednesday extends the streak.

Bear Case: Micron’s fiscal Q4 runs 14 weeks against Q1’s 13, meaning sequential guidance could look artificially soft purely on the calendar mismatch — and the stock has historically dropped an average of 3.44% in the week following its earnings report even after beating estimates, most recently falling 32.39% over the 30 days after a 15.74% report-day pop in June.

Technical Levels: Support sits at $1,053.98 (Monday’s close) and then $1,000 (psychological level); resistance sits at the all-time high of $1,255.00, with $1,100 marking the nearer-term ceiling some analysts have flagged.

Forecast: A beat-and-raise that addresses the fiscal-calendar guidance quirk directly on the call would likely be read as bullish even if the initial guidance print looks soft; a guidance miss with no such explanation risks reigniting the sharp post-earnings pullbacks Micron has shown in prior quarters.

Why This Matters: As the single largest scheduled earnings event of the week, Micron’s report will set the tone for the entire AI memory and semiconductor trade heading into October.

2. Summit Therapeutics (SMMT) | Trending Up 18% to 22% | Last Close $15.48

A $2 Billion AstraZeneca Bet Keeps Paying Off

Summit Therapeutics is trending up between 18% and 22% for a second consecutive session after AstraZeneca agreed to a $2 billion strategic equity investment priced at an effective $18.36 per share, a meaningful premium to where the stock had been trading.

Full Data & Technical Snapshot:

Catalysts & News: The AstraZeneca deal, structured through convertible preferred shares, ties Summit’s lead asset ivonescimab to additional combination studies and gives AstraZeneca what analysts described as “a seat at the table” for the broader PD-1/VEGF drug race, all while investors look ahead to a November 14 FDA decision on one of Summit’s indications. Akeso’s related HARMONi-GI1 biliary tract cancer trial also showed ivonescimab beating durvalumab plus chemotherapy on survival, progression-free survival and response rate, earning a Presidential Symposium slot at ESMO 2026.

Bull Case: A major pharma partner writing a $2 billion check above the prevailing market price is a strong external validation signal, and with HARMONi-3 progression-free survival data still ahead later this year, Summit has multiple additional binary catalysts that could extend the rally.

Bear Case: Summit remains a pre-revenue, cash-burning clinical-stage biotech with a deeply negative return on equity, and the stock’s 5-minute intraday tape around the deal news showed sharp spikes and quick pullbacks between $18 and $19.50 — a pattern that reflects speculative momentum as much as fundamental repricing.

Technical Levels: Support sits at $15.48 (Monday’s pre-news close) and then the mid-$15s marking the stock’s recent multi-week low; resistance sits at $18.36 (the AstraZeneca deal price) and then $19.50, the top of Tuesday’s intraday spike zone.

Forecast: A daily close that holds above the $18.36 deal price would confirm the market is pricing the AstraZeneca stake as a durable floor rather than a one-day news pop; a slide back toward $15.48 would suggest the rally is fading as quickly as it built.

Why This Matters: Summit’s back-to-back rally sessions make it one of the most closely watched biotech momentum stories heading into Wednesday, with the November FDA decision now looming as the next major catalyst.

3. Uranium Energy Corp (UEC) | Last Close $9.21 | Reports Around Wednesday

A Uranium Miner Trading Well Below Its Own Price Target

Uranium Energy Corp closed Monday at $9.21, down sharply from its January high of $20.34, even as the stock’s Burke Hollow production start and a 10-analyst average price target of $17.27 point to a business the Street still rates a Buy.

Full Data & Technical Snapshot:

Catalysts & News: Uranium Energy began production at its Burke Hollow in-situ recovery project in South Texas earlier this year and is pursuing a new domestic uranium refining plant as part of a broader push to expand U.S.-based uranium production, even as the stock has round-tripped from over $20 in January to under $10 today.

Bull Case: An 87.5% gap between the current price and the average analyst target, combined with genuine production growth at Burke Hollow and policy tailwinds supporting domestic uranium supply chains, gives Uranium Energy real upside if sentiment stabilizes.

Bear Case: The stock has fallen more than 25% in the past month alone, and revenue remains tiny relative to its market capitalization, with a deeply negative P/E ratio reflecting a business still years from consistent profitability.

Technical Levels: Support sits at the 52-week low of $8.91; resistance sits at $10.32 (Monday’s open) and then the psychological $12 level that capped several bounce attempts earlier this year.

Forecast: With earnings landing around Wednesday, commentary on production ramp at Burke Hollow and any update on the domestic refining plant will matter more to the stock’s trajectory than the headline quarterly loss figure.

Why This Matters: Uranium Energy’s report offers a genuine, under-the-radar test of whether the broader nuclear and uranium supply-chain theme still has legs after a rough stretch for the stock specifically.

4. Jabil Inc. (JBL) | Reports Before Wednesday’s Open

An Electronics Manufacturer With an EPS Bar Set High

Jabil reports fiscal Q4 2026 results before Wednesday’s open, with Wall Street modeling EPS of $4.06 per share for the diversified electronics manufacturing services provider.

Full Data & Technical Snapshot:

Catalysts & News: Jabil’s diversified manufacturing base spans data center infrastructure, healthcare, and industrial end markets, giving its results relevance as a read on capital spending trends across several sectors simultaneously — particularly its data center and cloud infrastructure exposure, which overlaps directly with the same AI buildout theme driving Micron’s earnings the same day.

Bull Case: Continued strong AI data center capital spending across Jabil’s hyperscaler customer base could drive a beat in its core cloud infrastructure segment, mirroring the demand strength Micron itself is expected to report hours later.

Bear Case: A diversified manufacturer with exposure to multiple end markets carries more moving parts than a single-product company, and any softness in Jabil’s healthcare or traditional industrial segments could offset strength in data center infrastructure.

Forecast: Segment-level commentary on data center and cloud infrastructure growth will be the most important detail to watch, given how directly it complements the broader AI infrastructure narrative playing out across Wednesday’s entire earnings slate.

Why This Matters: Jabil’s report, landing hours before Micron’s own AI-driven memory chip results, offers an early same-day cross-check on how strong AI infrastructure capital spending really is across the supply chain.

5. Conagra Brands (CAG) | Reports Before Wednesday’s Open

A Packaged Food Giant’s Report Card on the Grocery Aisle

Conagra Brands reports fiscal Q1 2027 results before Wednesday’s open, with analysts modeling EPS of $0.28 per share for the maker of Birds Eye, Slim Jim, and Healthy Choice.

Full Data & Technical Snapshot:

Catalysts & News: Conagra’s results will be parsed closely for commentary on private-label competition and promotional intensity across the frozen and snack food categories, a dynamic that has pressured several packaged food names throughout 2026 as consumers trade down to store brands amid persistent grocery inflation.

Bull Case: Any sign of stabilizing volume trends in Conagra’s core frozen food and snacks portfolio, paired with continued cost-savings execution, would suggest the worst of the private-label pressure has been absorbed into current guidance.

Bear Case: Packaged food companies broadly have struggled to grow volumes in 2026 even as pricing has held, and continued private-label share gains would signal Conagra’s premium branded portfolio is losing pricing power at the shelf.

Forecast: Organic volume growth, rather than the headline EPS number, will be the key metric determining whether Wednesday’s report reads as stabilization or continued deterioration in Conagra’s core categories.

Why This Matters: As one of the only major consumer staples names reporting this week, Conagra’s results offer a useful real-time gauge of household grocery spending resilience heading into the holiday season.

6. FactSet Research Systems (FDS) | Reports Before Wednesday’s Open

A Wall Street Data Provider’s Own Earnings Verdict

FactSet Research Systems reports fiscal Q4 2026 results before Wednesday’s open, with Wall Street modeling EPS of $4.35 per share for the financial data and analytics provider.

Full Data & Technical Snapshot:

Catalysts & News: FactSet’s subscription-based model, serving asset managers, hedge funds, and investment banks, makes its Annual Subscription Value metric a closely watched proxy for overall health in the financial services and asset management industry, an industry that has itself weathered a volatile 2026 marked by a Fed rate hike and shifting risk appetite.

Bull Case: Continued growth in Annual Subscription Value, particularly from AI-related data and analytics products aimed at institutional clients, would confirm FactSet’s platform is successfully monetizing the broader industry’s push toward AI-assisted research and trading tools.

Bear Case: Client budget pressure at asset managers and banks, some of which have faced their own margin compression this year, could translate into slower seat growth or subscription cancellations that weigh on FactSet’s recurring revenue base.

Forecast: Annual Subscription Value growth and retention rate commentary will matter more to the stock’s reaction than the headline EPS figure, given the subscription-driven nature of FactSet’s business model.

Why This Matters: FactSet’s results offer a rare, direct window into how the financial services industry itself is budgeting for data and technology spending amid a volatile year for markets.

7. Progress Software (PRGS) | Reports After Wednesday’s Close

A Software Company Digesting Its Biggest Acquisition Yet

Progress Software reports quarterly results after Wednesday’s close, with investors focused on management’s commentary on the $400 million Domo acquisition and what its integration means for future top- and bottom-line growth.

Full Data & Technical Snapshot:

Catalysts & News: The Domo deal represents one of Progress Software’s largest acquisitions in recent years, and Wednesday’s report will be the first opportunity for management to lay out concrete integration milestones and cross-selling opportunities across its combined application development, data connectivity, and business intelligence product lines.

Bull Case: Successful integration of Domo’s business intelligence and analytics capabilities into Progress’s existing developer tools portfolio could open meaningful cross-selling opportunities across both companies’ existing enterprise customer bases.

Bear Case: Large acquisitions carry real integration risk, and any disclosed delays or unexpected costs tied to combining Domo’s platform with Progress’s existing infrastructure could weigh on near-term margin guidance.

Forecast: Specific integration timeline commentary and any updated revenue synergy targets tied to Domo will be the most important data points for assessing whether the deal is tracking to plan.

Why This Matters: Progress Software’s report offers a timely test of how the market is pricing acquisition-driven growth stories in enterprise software, a segment that has seen more caution around large M&A this year.

8. Bassett Furniture Industries (BSET) | Reports After Wednesday’s Close

A Small-Cap Furniture Maker Nobody’s Watching Except Its Shareholders

Bassett Furniture Industries reports quarterly results after Wednesday’s close, offering one of the smallest and least-followed earnings reports of the entire week from the century-old furniture manufacturer and retailer.

Full Data & Technical Snapshot:

Catalysts & News: As a smaller, vertically integrated furniture manufacturer and retailer, Bassett’s results are highly sensitive to housing market activity and discretionary consumer spending on big-ticket home goods, a category that has been under pressure throughout 2026 amid elevated interest rates and a slower housing market.

Bull Case: Thin analyst coverage means genuine surprises, in either direction, tend to produce outsized stock reactions, and any sign of stabilizing demand in Bassett’s retail store network would be a positive signal for the broader home furnishings category.

Bear Case: Elevated mortgage rates following the Fed’s recent hike continue to weigh on new home sales and, by extension, big-ticket furniture purchases tied to home moves and renovations.

Forecast: Same-store sales trends across Bassett’s company-owned retail locations will be the clearest signal of whether furniture demand is stabilizing or continuing to soften into the fourth quarter.

Why This Matters: As one of the smallest, least-followed names reporting this week, Bassett offers a genuine opportunity for a surprise reaction that larger, more heavily analyzed stocks rarely produce.

9. Franklin Covey Co. (FC) | Reports After Wednesday’s Close

A Corporate Training Company Testing Enterprise Budget Health

Franklin Covey reports quarterly results after Wednesday’s close, with the leadership training and productivity software company offering a distinctive read on corporate training and development budgets.

Full Data & Technical Snapshot:

Catalysts & News: Franklin Covey’s subscription-based All Access Pass platform provides leadership and productivity training to large enterprise clients, making renewal rates and net new bookings a useful, if under-the-radar, signal of how corporate training budgets are holding up amid broader corporate cost discipline this year.

Bull Case: A subscription-based enterprise model with high renewal rates provides revenue visibility that many discretionary corporate spending categories lack, and any acceleration in new enterprise client additions would support continued growth.

Bear Case: Corporate training budgets are often among the first line items cut during periods of cost discipline, and any softness in net new bookings would signal enterprise clients are pulling back on discretionary development spending.

Forecast: Retention rate and net new enterprise bookings figures will matter far more to Franklin Covey’s stock reaction than the headline revenue number, given the subscription nature of its core business.

Why This Matters: As one of the few pure-play corporate training companies reporting this quarter, Franklin Covey’s results offer a distinctive, rarely-covered signal on enterprise spending priorities.

Sector Sentiment Snapshot & Forecast

Wednesday’s session splits into three distinct storylines. Micron’s earnings dominate the day as the single largest scheduled event of the week, with a near-unanimous Buy consensus and a 96% market-implied probability of an EPS beat setting an extremely high bar heading into the print. Summit Therapeutics’ continued rally offers a live test of whether a major pharma partner’s capital commitment can anchor a durable re-rating in a historically volatile biotech name, with the November FDA decision now the next major catalyst on the horizon.

And five overlooked mid-cap earnings reports (Jabil, Conagra, FactSet, Progress Software, Bassett Furniture, Franklin Covey) collectively span electronics manufacturing, packaged food, financial data, enterprise software, furniture, and corporate training — offering one of the more comprehensive single-day reads on both consumer and enterprise spending health available this quarter.

With Thursday kicking off a heavier October earnings calendar led by Accenture and Nike, Wednesday’s results will help set the tone for how the market approaches the next several weeks of corporate reporting.

At a Glance: Tomorrow’s Top Stocks to Watch

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and clinical-stage biotech, commodity-linked, and high-beta technology stocks carry elevated volatility risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change as trading continues. Several stocks discussed in this article had not yet reported earnings as of publication — actual results and subsequent market reactions may differ significantly from the estimates and expectations described here. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.

About The Author

Kasia Davis

See author's posts